Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (NASDAQ: CDXS) generates news primarily around its enzymatic technologies for therapeutics manufacturing and the development of its ECO Synthesis® / ECO Synthesis™ manufacturing platform. The company’s announcements frequently highlight progress in applying enzyme-based processes to small molecule pharmaceuticals manufacturing and nucleic acid synthesis, as well as steps toward enabling scaled manufacture of RNAi therapeutics, including siRNA and other oligonucleotides, through enzymatic routes.
News about Codexis often covers financial results and business updates, where the company reports on revenues, product gross margins, research and development spending, and strategic priorities. These releases typically include commentary on the performance of its Pharma Biocatalysis business, the status of ECO Synthesis-related activities, and the company’s cash position and funding plans as disclosed in its quarterly and annual reporting cycles.
Another recurring theme in Codexis news is collaborations and evaluation agreements with organizations involved in oligonucleotide therapeutics. The company has announced agreements with CDMOs and CRDMOs such as Nitto Denko Avecia and Axolabs to evaluate the ECO Synthesis manufacturing platform for therapeutic siRNA and other oligonucleotides. These updates describe how partners assess Codexis’s enzymatic approach and indicate that such evaluations may lead to licensing discussions and broader adoption.
Codexis also issues news about infrastructure and strategic initiatives, including the signing of a lease for a GMP manufacturing facility in Hayward, California, intended to support GMP manufacturing of siRNA and other oligonucleotides using ECO Synthesis. Additional releases detail organizational changes, leadership transitions, workforce streamlining aligned with an enhanced focus on ECO Synthesis, and participation in industry conferences such as TIDES USA and TIDES Europe, where Codexis and its collaborators present data on enzymatic manufacturing technologies.
Investors and observers who follow CDXS news can use this stream of updates to monitor Codexis’s progress in advancing enzyme-based manufacturing platforms, its relationships with manufacturing partners, and its evolving strategic focus within therapeutics manufacturing.
Codexis, Inc. (Nasdaq: CDXS) will report its Q3 2022 financial results on November 3, 2022, after market close. A conference call and webcast for discussing the results and providing a business update will follow at 4:30 p.m. ET. Participants can access the live webcast via Codexis' Investor Relations website. Codexis specializes in enzyme engineering, with applications in pharmaceuticals, food, and industrial products, aimed at improving sustainability and health outcomes.
Codexis, Inc. (NASDAQ: CDXS) has appointed Kevin Norrett as Chief Operating Officer (COO) to spearhead corporate growth and operational strategies. Norrett, with over 20 years in the biotech sector, including roles at Sierra Oncology and Angion Biomedica, will work with CEO Dr. Stephen Dilly. His appointment aims to strengthen Codexis' leadership in Performance Enzymes and Biotherapeutics, particularly in sustainable manufacturing for life sciences. Norrett expressed enthusiasm for converting Codexis' scientific innovations into commercial outcomes.
Codexis has appointed Dr. Rahul Singhvi to its Board of Directors, enhancing its leadership team. Dr. Singhvi, possessing over 30 years of biotechnology experience, previously held significant roles at Takeda, Novavax, and Merck. He is recognized for his expertise in drug development and biomanufacturing, currently serving as CEO of National Resilience. His addition is expected to bolster Codexis’ innovative product pipeline and further the company's mission in enzyme engineering and biotherapeutics. This strategic move is anticipated to drive growth and enhance market position.
Codexis, Inc. (NASDAQ: CDXS) hosted its Protein Engineering Forum on September 12-13, 2022, in San Francisco. This event attracted over 100 scientists and innovators to discuss advancements in genomics, nucleic acid synthesis, and synthetic biology. Keynote speaker Dr. Nicholas Turner highlighted innovations in biocatalysts. Attendees from more than 40 organizations exchanged insights, showcasing Codexis' role in facilitating collaboration in protein engineering. The company aims to drive sustainable advancements in pharmaceuticals and industrial products through its enzyme engineering capabilities.
Codexis (NASDAQ: CDXS) announced a strong financial performance for Q2 2022, with total revenue surging 51% to $38.4 million and product revenue rising 135% to $34.6 million, largely driven by sales related to Pfizer’s PAXLOVID™. The company reaffirmed its 2022 revenue guidance of $135M-$141M. Codexis is moving forward with significant partnerships, including a deal with Molecular Assemblies and a $5 million investment in seqWell. Leadership change was also announced, with Dr. Stephen Dilly set to succeed John Nicols as CEO on August 9, 2022.
Codexis (CDXS) and Molecular Assemblies have announced a Commercial License and Enzyme Supply Agreement, allowing Molecular Assemblies to use an advanced terminal deoxynucleotidyl transferase (TdT) enzyme in its Fully Enzymatic Synthesis™ (FES™) technology. This collaboration aims to enhance enzymatic DNA synthesis, producing high-quality oligonucleotides for applications in gene editing, next-generation sequencing, and synthetic biology. The agreement entails milestone payments and royalties, positioning both companies for accelerated commercial success in DNA synthesis.
Codexis, Inc. (NASDAQ: CDXS) has appointed Dr. Stephen Dilly as the new President and CEO, effective August 9, 2022. Dilly, a Codexis Board member and former CEO of Sierra Oncology, succeeds John Nicols, who is retiring after a decade of transformative leadership. Nicols will continue on the Board until June 2023 while transitioning to a Strategic Advisor role. Dr. Dilly brings over 30 years of experience in biopharmaceuticals, having previously led successful companies and developed numerous marketed drugs. Codexis aims to leverage its CodeEvolver platform for continued growth in enzyme engineering.
Codexis (NASDAQ: CDXS) has announced a multi-year agreement with Pfizer for supplying a high-performance enzyme crucial for producing nirmatrelvir, an active pharmaceutical ingredient in PAXLOVID™, which treats COVID-19. This partnership underscores Codexis’ rapid manufacturing capabilities and supports Pfizer's efforts to ensure the availability of this oral treatment globally. The agreement highlights Codexis’ role in advancing synthetic biology and improving pharmaceutical production efficiency.
Codexis (NASDAQ: CDXS) reported preliminary revenue results for Q2 2022, expecting approximately $38 million. Updated full-year revenue guidance is now projected between $135 million and $141 million. Product revenues from Pfizer are anticipated to reach the low end of $75 million to $80 million. The company notes a mix of fewer new deals and lower revenue from existing customers as reasons for the revised guidance. A detailed financial report will be released on August 4, 2022.
Codexis (NASDAQ: CDXS) has collaborated with Merck to publish a research paper in Science journal, focusing on enzyme engineering for site-selective synthesis of insulin bioconjugates. This partnership has led to significant innovations in the biotech field. Utilizing Codexis’ proprietary CodeEvolver® technology, the research outlines the development of specialized enzymes that enhance the precision of peptide modification, potentially creating new clinical leads. This collaboration underscores the promise of synthetic biology in improving therapeutic options.